Actively Recruiting
Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)
Led by Federation Francophone de Cancerologie Digestive · Updated on 2025-10-06
600
Participants Needed
20
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Keynote 117 phase III trial demonstrated the superiority of pembrolizumab (anti-PD1 monoclonal antibody) versus chemotherapy +/- targeted therapy in first-line treatment of dMMR/MSI metastatic colorectal cancer (mCRC). However, primary resistance to pembrolizumab was observed in approximately 20-30% of patients treated in the Keynote 177 study. Therefore, the identification of biomarkers predictive of resistance to immunotherapy for dMMR/MSI mCRC is necessary to better select patients who benefit the most from immunotherapy, and those for whom other therapeutic approaches should be favored.
CONDITIONS
Official Title
Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years old
- Histologically confirmed colorectal adenocarcinoma with unresectable metastasis(s)
- Receiving pembrolizumab as first-line immunotherapy treatment
- Tumor confirmed to have microsatellite instability by immunohistochemistry or molecular biology
You will not qualify if you...
- Having another cancer at the time of diagnosis that requires systemic treatment or affects prognosis
- Previous treatment with anti-PD1 or anti-PDL1 therapies
- Previous chemotherapy or targeted therapy for MSI/dMMR metastatic colorectal cancer
- Psychological or social conditions that may prevent follow-up, such as cognitive deficits or inability to remain in the same center
- Pregnancy
- Being under court protection or guardianship
- Opposing participation in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
Ch - Centre Hospitalier de La Côte Basque
Bayonne, France, 64100
Not Yet Recruiting
2
Ch - Ch Beauvais
Beauvais, France
Not Yet Recruiting
3
CH Jean Minjoz
Besançon, France, 25030
Not Yet Recruiting
4
Polyclinique Saint Privat
Boujan-sur-Libron, France, 34760
Actively Recruiting
5
Ch - Duchenne
Boulogne-sur-Mer, France
Not Yet Recruiting
6
Ch - Centre Hospitalier Metropole Savoie
Chambéry, France, 73011
Not Yet Recruiting
7
Ch - Centre Hospitalier de Cholet
Cholet, France, 49300
Not Yet Recruiting
8
CH - Compiegne
Compiègne, France
Not Yet Recruiting
9
Ch - Chd Vendée
La Roche-sur-Yon, France, 85925
Not Yet Recruiting
10
CH - Louis Pasteur
Le Coudray, France
Not Yet Recruiting
11
Centre Hospitalier Regional et Universitaire de Lille
Lille, France, 59037
Actively Recruiting
12
CH Saint Joseph - Saint Luc
Lyon, France, 69365
Not Yet Recruiting
13
Caluire et Cuire - Infirmerie Protestante de Lyon
Lyon, France
Not Yet Recruiting
14
Ch - Hôpital Saint Joseph
Marseille, France, 13285
Not Yet Recruiting
15
CH Saint Joseph
Marseille, France
Not Yet Recruiting
16
Centre Hospitalier
Mulhouse, France, 68070
Not Yet Recruiting
17
CHR D'Orleans - Hopital de la Source
Orléans, France, 45100
Not Yet Recruiting
18
Prive - Institut Montsouris
Paris, France
Actively Recruiting
19
Ch - Centre Hospitalier de Soisson
Soissons, France, 02209
Not Yet Recruiting
20
CH - Gustave Dron
Tourcoing, France
Not Yet Recruiting
Research Team
A
Aziz ZAANAN, MD, PhD
CONTACT
L
Leathicia NDONG, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here